Cardurion Pharmaceuticals Announces Appointment of Chris Morabito, M.D., as Chief Medical Officer
Appointment reflects growing strength and diversity of Cardurion’s pipeline July 08, 2020 08:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Chris Morabito, M.D., as chief medical officer […]
Cardurion Pharmaceuticals Announces Appointment of Peter Lawrence as President and Chief Executive Officer
April 15, 2020 07:30 AM Eastern Daylight Time BOSTON – (BUSINESS WIRE) – Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Peter S. Lawrence as president and chief executive officer. Mr. Lawrence joins Cardurion after […]
Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors
BOSTON, Mass. – November 20, 2019 – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced that it has consummated a private investment from Polaris Partners, a leading healthcare investment firm with a long history of partnering with entrepreneurs […]
Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure CRD-733 treatment reduced or reversed several markers of heart failure and reversed pressure overload-induced cardiac hypertrophy in animal models
November 12, 2018 09:00 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced preclinical results from its study of CRD-733, the company’s novel Phosphodiesterase-9 enzyme (PDE-9) inhibitor, in a poster presentation at the American Heart Association (AHA) […]
Silvia Priori, M.D., Ph.D. Delivers the William Harvey Lecture on Basic Science
CAMBRIDGE, MASS. – [October 2, 2018] – The European Society of Cardiology Congress holds four specialized lectures each year and selects four renowned scientists who are seen by their peers as leading experts in their corresponding fields. The William Harvey Lecture on Basic Science is a noteworthy accolade and recognizes a member of the scientific […]
Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure
CAMBRIDGE, MASS. – [September 20, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733, a Phosphodiesterase-9 (PDE-9) inhibitor in development to improve cardiac function […]
Cardurion Pharmaceuticals Appoints Jeb Keiper to Its Board of Directors
CAMBRIDGE, MASS. – [August 16, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of industry leader, Jeb Keiper, as an independent member of its Board of Directors. Mr. Keiper joins founder Michael Mendelsohn, M.D., Ken Novack, Ed Mascioli, M.D. […]
Cardurion Pharmaceuticals Appoints Rebecca Frey as Chief Operating Officer
CAMBRIDGE, MASS. – [July 24, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has expanded its leadership team with the addition of chief operating officer, Rebecca V. Frey, Pharm.D. “The expansion of our leadership team will not only […]
Cardurion Pharmaceuticals Announces Formation of Scientific and Clinical Advisory Board
CAMBRIDGE, MASS. – [June 26, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has assembled world-class Scientific and Clinical Advisory Boards. “Cardiovascular disease is the leading cause of death in both men and women and accounts for one-third of […]
Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate from Astellas
Company expanding pipeline of novel treatments for cardiovascular disease CAMBRIDGE, MASS. – [April 16, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced it has entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733, a PDE-9 inhibitor with […]
